

The Manager
Company Announcements Office
ASX Limited

CANCELLATION OF OPTIONS

Adelaide, 23 October 2018: Further to the announcement of the resignation of a Director, the following options have not vested as at the date of resignation and therefore under the Options Terms and Conditions are cancelled;

- 500,000 Unlisted Options exercisable at \$0.30, expiring 30 November 2027.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software, and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation. For more information, see www.lbtinnovations.com

CONTACTS

| LBT Innovations | Investor Enquiries | Media Relations |
|---|---|--|
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com | David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com | Sarah Kemter Monsoon Communications Tel: +61 3 9620 3333 E: sarahk@monsoon.com.au |